EP2233150A3 - Erythropoietin for use in the treatment of wounds or the transplantation of cells - Google Patents

Erythropoietin for use in the treatment of wounds or the transplantation of cells Download PDF

Info

Publication number
EP2233150A3
EP2233150A3 EP10005293A EP10005293A EP2233150A3 EP 2233150 A3 EP2233150 A3 EP 2233150A3 EP 10005293 A EP10005293 A EP 10005293A EP 10005293 A EP10005293 A EP 10005293A EP 2233150 A3 EP2233150 A3 EP 2233150A3
Authority
EP
European Patent Office
Prior art keywords
epo
liver
cells
treatment
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10005293A
Other languages
German (de)
French (fr)
Other versions
EP2233150B1 (en
EP2233150A2 (en
Inventor
Augustinus Bader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03029961A external-priority patent/EP1550715A1/en
Priority claimed from DE10361813A external-priority patent/DE10361813A1/en
Application filed by Individual filed Critical Individual
Priority to EP10005293.5A priority Critical patent/EP2233150B1/en
Priority to PL10005293T priority patent/PL2233150T3/en
Publication of EP2233150A2 publication Critical patent/EP2233150A2/en
Publication of EP2233150A3 publication Critical patent/EP2233150A3/en
Application granted granted Critical
Publication of EP2233150B1 publication Critical patent/EP2233150B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Abstract

Use of hematopoietic growth factors (I), especially erythropoietin (EPO), thrombopoietin (TPO) or their derivatives, analogs and fragments, to prepare a composition for structural regeneration of tissue, is new. Independent claims are also included for the following: (1) similar use of an EPO-inducing factor (II); (2) carrier structure containing at least one (I) or (II); (3) preparing the structure of (2); and (4) composition comprising cells (A) that have been pretreated, in vitro, with (I). ACTIVITY : Hepatotropic; Osteopathic; Cardiant; Ophthalmological; Uropathic; Antiinflammatory; Antiulcer; Vulnerary; Neuroprotective. Part of the liver was removed from pigs, then the animals (a) given no treatment; (b) treated locally with 10 4> units EPO and a fibrin glue; or (c) treated systemically with 10 4> units EPO on days 0, 3, 7 and 11. After 14 days, the mean liver volume (ml) was (a) 892; (b) 894 and (c) 1073, and liver weight (g) was (a) 1001; (b) 1027 and (c) 1249; where these results for (c) are statistically significant at p less than 0.05. MECHANISM OF ACTION : Promoting regrowth of tissue.
EP10005293.5A 2003-12-30 2004-12-30 Erythropoietin for use in the treatment of wounds or the transplantation of cells Active EP2233150B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10005293.5A EP2233150B1 (en) 2003-12-30 2004-12-30 Erythropoietin for use in the treatment of wounds or the transplantation of cells
PL10005293T PL2233150T3 (en) 2003-12-30 2004-12-30 Erythropoietin for use in the treatment of wounds or the transplantation of cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03029961A EP1550715A1 (en) 2003-12-30 2003-12-30 Method for the regeneration of tissue
DE10361813A DE10361813A1 (en) 2003-12-30 2003-12-30 Using hematopoietic growth factors for structural regeneration of tissue, useful e.g. for treating liver damage and wounds
EP10005293.5A EP2233150B1 (en) 2003-12-30 2004-12-30 Erythropoietin for use in the treatment of wounds or the transplantation of cells
EP04804424A EP1699915B1 (en) 2003-12-30 2004-12-30 Use of erythropoietin for liver tissue regeneration

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP04804424.2 Division 2004-12-30
EP04804424A Division EP1699915B1 (en) 2003-12-30 2004-12-30 Use of erythropoietin for liver tissue regeneration

Publications (3)

Publication Number Publication Date
EP2233150A2 EP2233150A2 (en) 2010-09-29
EP2233150A3 true EP2233150A3 (en) 2013-01-09
EP2233150B1 EP2233150B1 (en) 2016-09-07

Family

ID=34740522

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04804424A Active EP1699915B1 (en) 2003-12-30 2004-12-30 Use of erythropoietin for liver tissue regeneration
EP10005293.5A Active EP2233150B1 (en) 2003-12-30 2004-12-30 Erythropoietin for use in the treatment of wounds or the transplantation of cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP04804424A Active EP1699915B1 (en) 2003-12-30 2004-12-30 Use of erythropoietin for liver tissue regeneration

Country Status (14)

Country Link
US (2) US7910547B2 (en)
EP (2) EP1699915B1 (en)
JP (2) JP4903580B2 (en)
AT (1) ATE469654T1 (en)
AU (2) AU2004309083B2 (en)
BR (1) BRPI0418326A (en)
CA (1) CA2550301A1 (en)
DE (1) DE502004011252D1 (en)
DK (2) DK1699915T3 (en)
ES (2) ES2606068T3 (en)
PL (2) PL2233150T3 (en)
PT (1) PT1699915E (en)
RU (2) RU2392314C2 (en)
WO (1) WO2005063965A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026480A1 (en) * 2000-05-29 2001-12-13 Augustinus Bader Method of making a recipient-specific tissue graft or implant
EP1699915B1 (en) 2003-12-30 2010-06-02 Augustinus Bader Use of erythropoietin for liver tissue regeneration
JP4982841B2 (en) * 2005-10-12 2012-07-25 国立大学法人名古屋大学 Regenerative medical bone composition
US20080107632A1 (en) * 2006-09-06 2008-05-08 Henrich Cheng Fibrin glue composition for repairing nerve damage and methods thereof
JP4696247B2 (en) * 2006-12-11 2011-06-08 国立大学法人 筑波大学 Liver fibrosis inhibitor
JP5098018B2 (en) * 2007-03-06 2012-12-12 国立大学法人 筑波大学 Hepatitis treatment agent
AR065613A1 (en) * 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd PROTECTION AGENTS FOR TRANSPLANTED ORGANS
EP2018835B1 (en) 2007-07-09 2014-03-05 Augustinus Bader Agent-eluting plaster
PL2192907T3 (en) 2007-08-16 2018-10-31 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for therapeutic applications
WO2009083203A2 (en) * 2007-12-28 2009-07-09 Heraeus Kulzer Gmbh Topical application and formulation of erythropoietin for skin wound healing
WO2009089324A1 (en) * 2008-01-08 2009-07-16 Yale University Compositions and methods for promoting patency of vascular grafts
US20100310626A1 (en) * 2008-01-24 2010-12-09 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for bone regeneration
US8470369B2 (en) * 2008-03-10 2013-06-25 Marfly 2, L.P Bone paste composition
JP2011516436A (en) * 2008-03-31 2011-05-26 バーダー、アウグスティヌス Methods and compositions for tissue regeneration using stem cells or bone marrow cells
CA2748147C (en) * 2008-12-24 2017-06-20 Augustinus Bader Rapid preparation and use of engineered tissue and scaffolds as individual implants
US20100272816A1 (en) * 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
JP2013520168A (en) * 2010-02-22 2013-06-06 プレジデント アンド フェロウズ オブ ハーバード カレッジ Method for generating engineered innervating tissue and use thereof
WO2011104707A1 (en) * 2010-02-23 2011-09-01 Remedor Biomed Ltd. Methods and compositions for enhancing fat graft survival
US20130149349A1 (en) 2010-06-03 2013-06-13 Indiana University Research And Technology Corporation Use of compounds with thrombopoietic activity to promote bone growth and healing
EP2590666B1 (en) 2010-07-06 2017-04-26 Augustinus Bader Topical application of erythropoietin for use in the treatment of injuries of the cornea
WO2012031778A1 (en) 2010-09-12 2012-03-15 Augustinus Bader Use of erythropoietin for scar-free healing of wounds or tissue defects
WO2012148200A2 (en) * 2011-04-26 2012-11-01 아주대학교 산학협력단 Composition for aiding surgical procedures for treating ischemic vascular diseases
US11311367B2 (en) 2012-01-31 2022-04-26 Wake Forest University Health Sciences Tissue-engineered gut-sphincter complexes and methods of making the same
WO2013116446A1 (en) * 2012-01-31 2013-08-08 Wake Forest University Health Sciences Tubular bioengineered smooth muscle structures
US9795965B2 (en) * 2013-01-03 2017-10-24 Brigham And Women's Hospital, Inc. System and method for a biomimetic fluid processing
RU2522816C1 (en) * 2013-02-12 2014-07-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Composition for cell-replacement therapy of soft tissue defects
CN106414703B (en) 2014-03-31 2019-10-18 布里格姆女子医院有限公司 The system and method for bionical fluid processing
JP2016067312A (en) * 2014-09-30 2016-05-09 株式会社ジーシー Cartilage differentiation culture medium, and cartilage
RU2582948C1 (en) * 2014-10-23 2016-04-27 Ренат Рашитович Ахмеров Method for soft tissue augmentation by means of heat-processed platelet-rich autoplasma
US10232048B1 (en) * 2014-11-18 2019-03-19 Divine Api-Logics, LLC Apitherapy method and composition
US20180296706A1 (en) * 2015-10-05 2018-10-18 Board Of Regents, The University Of Texas System Micro-and nano-device for cartilage injury detection and treatment
WO2017100782A1 (en) 2015-12-11 2017-06-15 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patent specific tissue engineering vascular grafts
CN108367007A (en) * 2015-12-16 2018-08-03 第三共株式会社 Therapeutic agent for wound
US20190015190A1 (en) 2015-12-30 2019-01-17 Wake Forest University Health Sciences Tissue-engineered gut-sphincter complexes and methods of making the same
RU2638796C1 (en) * 2016-08-05 2017-12-15 Общество с ограниченной ответственностью "Покровский банк стволовых клеток" Method for obtaining of two-component preparation for treatment of joints damage by low-invasive introduction into joint bag and preparation obtained by this method
CN110234311B (en) 2016-11-10 2022-08-12 Asc瑞珍尼特有限公司 Cosmetic preparation for topical application containing erythropoietin-derived molecules
RU2648869C1 (en) * 2017-04-03 2018-03-28 Анатолий Владимирович Толстов Method for treatment of local burn wounds of ii-iii a degree
RU2650214C1 (en) * 2017-04-04 2018-04-11 федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) Method of combined osteoplastic surgery of paranasal sinus with the use of the growth factor
RU2666595C1 (en) * 2017-09-26 2018-09-11 федеральное государственное бюджетное образовательное учреждение высшего образования Кубанский государственный медицинский университет Министерства Здравоохранения Российской Федерации ФГБОУ ВО КубГМУ Минздрава России Hydrogel for correcting the post-trepanation defect of the skull
EP3768222A4 (en) * 2018-03-20 2021-12-22 University of Pittsburgh - Of the Commonwealth System of Higher Education Regeneration of vital tooth pulp
US20210106718A1 (en) * 2019-10-14 2021-04-15 Board Of Regents, The University Of Texas System Mussel inspired nancomposite adhesives for biomedical applications
CN113521049A (en) * 2021-07-29 2021-10-22 姚雷利 Stretch mark demolding repair method
WO2023168153A1 (en) * 2022-03-03 2023-09-07 Fibrobiologics, Inc. Therapeutic use of fibroblasts to stimulate regeneration and repair of atrophied spleen
WO2023210713A1 (en) * 2022-04-27 2023-11-02 国立大学法人京都大学 Epicardial cell regeneration promoter and method for promoting epicardial cell regeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660905B1 (en) * 1999-07-14 2003-12-09 The Board Of Trustees Of The Leland Stanford Junior University Mice comprising engrafted functional human hepatocytes
WO2004001023A2 (en) * 2002-06-20 2003-12-31 Bionethos Holding Gmbh Method and device for multiplying and differentiating cells in the presence of growth factors and of a biological matrix or of a supporting structure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6008047A (en) 1993-04-08 1999-12-28 Livercell L.L.C. Cell culturing method and medium
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
ATE354377T1 (en) * 1993-12-02 2007-03-15 Max Delbrueck Centrum ANTITUMOR AGENT CONTAINING A CYTOSTATIC AND A CONTRAST AGENT
CA2183266A1 (en) 1994-02-14 1995-08-17 Richard D. Holly Hematopoietic protein and materials and methods for making it
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
CZ288926B6 (en) 1994-03-31 2001-09-12 Amgen Inc. MGDF derivative, process of its preparation and pharmaceutical preparation in it is comprised
US7008634B2 (en) * 1995-03-03 2006-03-07 Massachusetts Institute Of Technology Cell growth substrates with tethered cell growth effector molecules
US5879673A (en) 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
RU2115748C1 (en) * 1996-11-19 1998-07-20 Открытое акционерное общество "АВИСМА титано-магниевый комбинат" Method of processing effluent gases from magnesium production enterprises
DE59803925D1 (en) 1997-06-27 2002-05-29 Augustinus Bader BIOARTIFICIAL TRANSPLANT AND METHOD FOR THE PRODUCTION THEREOF
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6776984B1 (en) * 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DE10034583A1 (en) 2000-07-14 2002-01-31 Axel Haverich Individual venous valve prosthesis
AU2001290312A1 (en) * 2000-10-16 2002-04-29 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
DE60144439D1 (en) 2000-12-20 2011-05-26 Hoffmann La Roche CONJUGATES OF ERYTHROPOIETIN (EPO) WITH POLYETHYLENE GLYCOL (PEG)
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EP1499190A4 (en) * 2001-05-17 2005-06-15 Univ Illinois Methods for treating liver disease and liver damage with growth hormone and foxm1b
EP1406680A4 (en) * 2001-06-15 2007-01-10 Johns Hopkins Singapore Pte Lt Biofunctional fibers
DE60239217D1 (en) * 2001-11-16 2011-03-31 Childrens Medical Center GENERATION OF WOVEN TECHNOLOGY MANUFACTURED FEMALE REPRODUCTIVE ORGANS
DE10234192B4 (en) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Use of erythropoietin
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
DE10303584A1 (en) * 2003-01-30 2004-08-12 Stauss, Robert, Dr. Erythropoietin is applied as a coating material to medical implants to improve the acceptance behavior of relevant body tissues
EP1699915B1 (en) * 2003-12-30 2010-06-02 Augustinus Bader Use of erythropoietin for liver tissue regeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660905B1 (en) * 1999-07-14 2003-12-09 The Board Of Trustees Of The Leland Stanford Junior University Mice comprising engrafted functional human hepatocytes
WO2004001023A2 (en) * 2002-06-20 2003-12-31 Bionethos Holding Gmbh Method and device for multiplying and differentiating cells in the presence of growth factors and of a biological matrix or of a supporting structure

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BARON FRÉDÉRIC ET AL: "Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 30, no. 6, 1 June 2002 (2002-06-01), pages 546 - 554, XP009157801, ISSN: 0301-472X, [retrieved on 20020605], DOI: 10.1016/S0301-472X(02)00795-6 *
BILIR B M ET AL: "Hepatocyte transplantation in acute liver failure", LIVER TRANSPLANTATION, SAUNDERS, PHILADELPHIA, PA, US, vol. 6, no. 1, 1 January 2000 (2000-01-01), pages 32 - 40, XP026696479, ISSN: 1527-6465, [retrieved on 20000101] *
BUEMI MICHELE ET AL: "Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps.", ACTA DERMATO-VENEREOLOGICA 2002 LNKD- PUBMED:12575845, vol. 82, no. 6, 2002, pages 411 - 417, XP002993404, ISSN: 0001-5555 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 2000 (2000-09-01), SUGIYAMA N ET AL: "Intraportal administration of low-dose recombinant human hepatocyte growth factor enhances effects of hepatocellular transplantation.", XP002687836, Database accession no. NLM11100324 *
DEMPKE W ET AL: "HUMAN HEMATOPOIETIC GROWTH FACTORS: OLD LESSONS AND NEW PERSPECTIVES", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 20, no. 6D, 5 December 1999 (1999-12-05), pages 5155 - 5164, XP009005227, ISSN: 0250-7005 *
FATOUROS M ET AL: "Alterations in body weight, breaking strength, and wound healing in Wistar rats treated pre- and postoperatively with erythropoietin or granulocyte macrophage-colony stimulating factor: evidence of a previously unknown anabolic effect of erythropoietin?", THE JOURNAL OF LABORATORY AND CLINICAL MEDICINE MAR 1999, vol. 133, no. 3, March 1999 (1999-03-01), pages 253 - 259, XP009158639, ISSN: 0022-2143 *
GALEANO M ET AL: "Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse", DIABETES, AMERICAN DIABETES ASSOCIATION, US, vol. 53, no. 9, 1 September 2004 (2004-09-01), pages 2509 - 2517, XP002637869, ISSN: 0012-1797 *
HAROON ZISHAN A ET AL: "A novel role for erythropoietin during fibrin-induced wound-healing response.", AMERICAN JOURNAL OF PATHOLOGY, vol. 163, no. 3, September 2003 (2003-09-01), pages 993 - 1000, XP002674608, ISSN: 0002-9440 *
LECKEL K ET AL: "[State of hepatocyte transplantation: a risk or a chance?].", ZENTRALBLATT FÜR CHIRURGIE APR 2003, vol. 128, no. 4, April 2003 (2003-04-01), pages 283 - 290, XP009165041, ISSN: 0044-409X *
MILLER C B ET AL: "Erythropoietin in stem cell transplantation.", BONE MARROW TRANSPLANTATION MAY 2001, vol. 27, no. 10, May 2001 (2001-05-01), pages 1011 - 1016, XP002687666, ISSN: 0268-3369 *
MOGHTADER ET AL: "The use of recombinant human erythropoietin and cultured epithelial autografts in a Jehovah's witness with a major thermal injury", BURNS, BUTTERWORTH HEINEMANN, GB, vol. 20, no. 2, 1 April 1994 (1994-04-01), pages 176 - 177, XP022220358, ISSN: 0305-4179, DOI: 10.1016/S0305-4179(06)80019-7 *
ROCHE R J: "Does human recombinant erythropoietin improve wound healing?", JOURNAL OF THE AMERICAN GERIATRICS SOCIETY JAN 1995 LNKD- PUBMED:7806748, vol. 43, no. 1, January 1995 (1995-01-01), pages 81, XP009157788, ISSN: 0002-8614 *
SUGIYAMA N ET AL: "Intraportal administration of low-dose recombinant human hepatocyte growth factor enhances effects of hepatocellular transplantation.", HEPATO-GASTROENTEROLOGY 2000 SEP-OCT, vol. 47, no. 35, September 2000 (2000-09-01), pages 1245 - 1249, ISSN: 0172-6390 *
WILLIAMSON ET AL: "Erythropoietin", TRANSFUSION SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 12, no. 1-2, 1 January 1991 (1991-01-01), pages 15 - 23, XP022645740, ISSN: 0955-3886, [retrieved on 19910101], DOI: 10.1016/0955-3886(91)90005-N *

Also Published As

Publication number Publication date
US7910547B2 (en) 2011-03-22
PL1699915T3 (en) 2010-11-30
PL2233150T3 (en) 2017-06-30
DK2233150T3 (en) 2016-12-12
RU2542391C2 (en) 2015-02-20
US20110172150A1 (en) 2011-07-14
PT1699915E (en) 2010-08-31
ATE469654T1 (en) 2010-06-15
AU2004309083B2 (en) 2010-11-11
JP4903580B2 (en) 2012-03-28
EP2233150B1 (en) 2016-09-07
US20080031850A1 (en) 2008-02-07
AU2011200538B2 (en) 2012-02-23
DE502004011252D1 (en) 2010-07-15
RU2010105646A (en) 2011-08-27
WO2005063965A1 (en) 2005-07-14
ES2606068T3 (en) 2017-03-17
DK1699915T3 (en) 2010-09-13
CA2550301A1 (en) 2005-07-14
EP1699915A1 (en) 2006-09-13
JP2007517001A (en) 2007-06-28
RU2392314C2 (en) 2010-06-20
AU2004309083A1 (en) 2005-07-14
RU2006120458A (en) 2008-02-10
EP2233150A2 (en) 2010-09-29
EP1699915B1 (en) 2010-06-02
ES2346226T3 (en) 2010-10-13
JP2012067117A (en) 2012-04-05
AU2011200538A1 (en) 2011-03-03
BRPI0418326A (en) 2007-05-02

Similar Documents

Publication Publication Date Title
EP2233150A3 (en) Erythropoietin for use in the treatment of wounds or the transplantation of cells
ES2351875T3 (en) USE OF INHIBITORS OF LISIL OXIDASES FOR CELL CULTURE AND TISSULAR ENGINEERING.
KR101422689B1 (en) Cell therapy product for cartilage damage comprising collagen, hyaluronic acid derivative and mammalian umbilical cord-derived stem cells
Navsaria et al. Culturing skin in vitro for wound therapy
ATE188383T1 (en) MIXTURES FOR PROTECTING AND REGENERATING TISSUES
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
CA2387542A1 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
EP1077254A3 (en) Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
JPS59192364A (en) Soft bone and repairing method thereof
JP2006510399A (en) Treatment of tissue with undifferentiated mesenchymal cells
NZ517772A (en) Cytotoxic agents comprising taxanes and their therapeutic use
HK1038890B (en) Methods and compositions for healing and repair of articular cartilage
ATE106743T1 (en) STABILIZED PREPARATIONS CONTAINING FGF.
NO924323L (en) NEW HYBRID TRANSFORMING GROWTH FACTORS
DE69634982D1 (en) PROCESS FOR INCREASING HEMATOPOIETIC CELLS
EP1405906A4 (en) Schwann cells originating in myeloid interstitial cells
PT941329E (en) METHOD FOR PREVENTING REJECTION OF RIPES IN TRANSPLANTATION AND TO PRODUCE A HOST CELL FOR UNIVERSAL GENETIC THERAPY USING LYMPHOCYTE ACTIVATION (LAG-3)
NO20013744D0 (en) Methods and compositions for healing and repair of articular cartilage
Tan et al. Low-intensity pulsed ultrasound (LIPUS) and pulsed electromagnetic field (PEMF) treatments affect degeneration of cultured articular cartilage explants
ATE359798T1 (en) USE OF DEXTRANSULPHATE TO TREAT IBMIR
PT1198557E (en) QUEERATINOCITO IMPROVED CULTURE AND ITS UTILIZATIONS
CN109576213B (en) Preparation method and application of melanocyte fluid
EP1331264B1 (en) Method of culturing human chondrocytes
CA2320423A1 (en) Derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies
RU2452527C1 (en) Method of cartilage hyaline neogenesis accompanying early destructive diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100607

AC Divisional application: reference to earlier application

Ref document number: 1699915

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/18 20060101AFI20120503BHEP

Ipc: A61P 17/02 20060101ALI20120503BHEP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/407 20060101ALI20121127BHEP

Ipc: A61P 17/02 20060101ALI20121127BHEP

Ipc: A61P 1/16 20060101ALI20121127BHEP

Ipc: A61K 35/12 20060101ALI20121127BHEP

Ipc: A61K 38/18 20060101AFI20121127BHEP

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20140523

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160428

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1699915

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 826236

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161015

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502004015308

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20161208

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENT- UND MARKENANWAELTE, CH

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160907

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160907

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161208

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2606068

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160907

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160907

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170107

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160907

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161207

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160907

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170109

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502004015308

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20170608

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160907

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160907

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161230

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161230

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20041230

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160907

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20221220

Year of fee payment: 19

Ref country code: BE

Payment date: 20221226

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20221216

Year of fee payment: 19

Ref country code: ES

Payment date: 20230118

Year of fee payment: 19

Ref country code: CH

Payment date: 20221228

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20221227

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231219

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231222

Year of fee payment: 20

Ref country code: NL

Payment date: 20231226

Year of fee payment: 20

Ref country code: IT

Payment date: 20231221

Year of fee payment: 20

Ref country code: FR

Payment date: 20231226

Year of fee payment: 20

Ref country code: DK

Payment date: 20231222

Year of fee payment: 20

Ref country code: AT

Payment date: 20231219

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231221

Year of fee payment: 20

Ref country code: BE

Payment date: 20231226

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240119

Year of fee payment: 20